1449752-98-0

Upstream product

• 56651-60-6 4-methoxybenzyl isocyanate 
• 1449694-06-7 1-((2R,3S,3aS,9aR)-2-hydroxy-5-oxo-2,3,3a,4,5,9a-hexahydro-1H-cyclopenta[e]pyrrolo[1,2-a]pyrazin-3-yl)-3-(4-methoxybenzyl)urea 
• 1449694-07-8 (5aS,5bS,8aS,9aR)-8a-hydroxy-8-(4-methoxybenzyl)-5,5a,5b,6,8,8a,9,9a-octahydroimidazo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazine-4,7-dione 
• 1092096-40-6 C₁₀H₁₃N₃O₂ 
• 1092096-33-7 (1R,9S,10S,14R)-13-oxa-2,8,11-triazatetracyclo[7.6.0.0^2,6.0^10,14]pentadeca-3,5-diene-7,12-dione 

Relevant academic research and scientific papers

TREATING BRAIN CANCER USING AGELASTATIN A (AA) AND ANALOGUES THEREOF

This document relates to compounds and compositions useful for treating cancers, such as brain and nervous system cancers.

An integrated approach to the discovery of potent agelastatin A analogues for brain tumors: Chemical synthesis and biological, physicochemical and CNS pharmacokinetic analyses

(-)-Agelastatin A (AA), isolated from the coral sea axinellid sponge Agelas dendromorpha, has shown a high antineoplastic activity. We have synthesized eighteen AA analogues and analyzed their cytotoxicities towards three cancer cell lines. By the structure-activity relationship (SAR) study, we identified three novel analogues with higher or comparable cytotoxic activities to AA. They were subjected to chemoinformatic analysis, which revealed physicochemical properties favoring excellent central nervous system (CNS) penetration. CNS pharmacokinetic analysis in murine models validated the chemoinformatic prediction and revealed that these analogues indeed had better CNS penetration than AA. These novel potent AA analogues deserve further evaluation for therapeutic use against cancers, particularly primary and secondary brain tumors.